MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston Sells 3,000 Shares

MaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston sold 3,000 shares of the firm’s stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $3.72, for a total value of $11,160.00. Following the transaction, the director now directly owns 141,950 shares in the company, valued at approximately $528,054. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

John Joseph Johnston also recently made the following trade(s):

• On Thursday, September 26th, John Joseph Johnston sold 3,000 shares of MaxCyte stock. The shares were sold at an average price of $3.82, for a total transaction of $11,460.00.
• On Monday, August 26th, John Joseph Johnston sold 3,000 shares of MaxCyte stock. The stock was sold at an average price of $4.28, for a total transaction of $12,840.00.

MaxCyte Stock Performance

NASDAQ:MXCT traded down $0.03 during trading hours on Wednesday, reaching $3.54. The company’s stock had a trading volume of 279,457 shares, compared to its average volume of 507,705. The firm has a market capitalization of $372.30 million, a price-to-earnings ratio of -10.50 and a beta of 1.39. The firm has a 50-day simple moving average of $3.93 and a 200-day simple moving average of $4.19. MaxCyte, Inc. has a 1 year low of $2.92 and a 1 year high of $5.55.

MaxCyte (NASDAQ:MXCT) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.05. MaxCyte had a negative return on equity of 15.52% and a negative net margin of 77.97%. The firm had revenue of $10.43 million for the quarter, compared to the consensus estimate of $8.20 million. During the same quarter in the previous year, the business earned ($0.10) earnings per share. Equities analysts anticipate that MaxCyte, Inc. will post -0.44 earnings per share for the current fiscal year.

Institutional Trading of MaxCyte

Several hedge funds and other institutional investors have recently bought and sold shares of MXCT. Price T Rowe Associates Inc. MD increased its stake in shares of MaxCyte by 20.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 25,199 shares of the company’s stock worth $106,000 after buying an additional 4,320 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of MaxCyte by 22.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,735 shares of the company’s stock valued at $128,000 after acquiring an additional 5,927 shares during the period. PNC Financial Services Group Inc. bought a new position in shares of MaxCyte during the fourth quarter valued at about $29,000. Russell Investments Group Ltd. purchased a new stake in shares of MaxCyte during the first quarter worth about $28,000. Finally, Creative Planning grew its stake in shares of MaxCyte by 33.6% in the third quarter. Creative Planning now owns 28,652 shares of the company’s stock worth $111,000 after purchasing an additional 7,212 shares during the last quarter. Institutional investors own 68.81% of the company’s stock.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.